Tali Digital Ltd.

Integration of a voice-enabled AI assistant with Net Health, a leader in specialized healthcare technology, will speed EHR documentation and offer providers more time with patients PITTSBURGH, Pa., Oct. 23, 2024 /PRNewswire/ -- Net Health, a trusted source for specialized software solutions that empower restorative care providers across the continuum of care, today announced that it has commenced a strategic technology partnership with Tali, a leading AI assistant and ambient clinical documentation solution. The new integration will revolutionize EHR documentation through AI technology by infusing Net Health EHR software with Tali's voice-enabled AI assistant. Clinicians can expect streamlined workflows that will set a new standard of documentation accuracy and efficiency in specialty care settings, enabling them to optimize time with patients. Once complete, the Tali solution will be available in the following Net Health EHRs: Optima for post-acute and senior living facilities; ReDoc for hospital outpatient; TherapySource for physical therapy; and WoundExpert for wound care. "Our integration with Tali AI is intended to give providers a substantial amount of time back with their patients," said Ron Books, Chief Executive Officer of Net Health. "We recognize the urgency to deliver solutions that meet the needs of both patients and providers, which is why we prioritize strategic technology integrations and partnerships. Our work with Tali AI is a reflection of this commitment. We will continue to provide cutting-edge solutions that promote positive patient outcomes and business growth." According to a recent AIM study, clinicians spend nearly 50% of their day manually documenting within EHR systems and doing desk work. The AIM 2024 survey of U.S. physicians also shows that reducing medical documentation burden has significantly helped to decrease clinician burnout since 2020. However, in fields like physical therapy where there are significant provider shortages – the American Physical Therapy Association (APTA) has estimated that over 26,000 jobs will not be able to be filled by 2025 – providers are still managing increased workloads and would benefit immensely from reduced administrative burden. The integration of ambient documentation will allow providers who use Net Health to remain engaged and connected with their patients while the AI medical scribe captures conversations in real time. Once the encounter is complete, AI technology will analyze the transcription and generate high-quality clinical documentation in seconds, which can be reviewed and edited as required. The tool is designed to reduce the time clinicians spend on paperwork, thus empowering them to shift their focus to clinical priorities rather than administrative tasks. "With Net Health's comprehensive EHR offerings and dominant market footprint, we are confident that together we can ease provider burnout and help improve overall care in these critical areas," said Kevin Keenahan, Chief Product Officer of Net Health. "By formalizing our integration with Tali, we're taking a massive step towards empowering healthcare providers with next-level solutions that will transform their day-to-day lives." "Tali is deeply familiar with the patterns, rhythms, and needs of today's healthcare providers, and the company brings extensive technical expertise and a medical perspective to this relationship," said Mahshid Yassaei, Chief Executive Officer of Tali AI. "Merging Tali's technology with Net Health's industry-leading products, the two companies are poised to dramatically improve the quality of life for thousands of clinicians." The addition of Tali's voice-enabled interface differentiates Net Health from other EHR solutions as a next-generation technology offering that enhances both functionality and user experience. By incorporating AI-assisted technology, healthcare providers can significantly reduce time spent on clinical documentation, enabling them to focus more on patient care. This tool also improves accuracy and efficiency, helping Net Health clients strengthen their businesses and increase revenue. As AI continues to shape the future of healthcare, this integration will help ensure Net Health's ongoing innovation and growth throughout specialty care settings. To learn more about Net Health and the integration with Tali, visit: About Net Health Net Health is a trusted source for more than 25,000 healthcare organizations across the continuum of care. Our specialized software solutions enable restorative care providers and their organizations to improve both patient outcomes and financial performance. Over 30 years of expertise in wound care and rehab therapy inform our electronic health record (EHR) software, patient engagement tools, and predictive analytics. Our technology platforms help administrators manage workflow, specialists engage with patients, and executives drive business growth. Net Health is a portfolio company of The Carlyle Group, Level Equity, and Silversmith Capital Partners. Learn more at . About Tali Tali AI is a voice-enabled AI healthcare technology that facilitates documentation of millions of patient encounters annually. The company is revolutionizing healthcare provider workflows and elevating patient care by reducing the time and energy healthcare providers spend on documentation and administrative tasks. For more information on Tali AI, visit . SOURCE Net Health Systems, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

不久前，数字疗法代表企业Pear Therapeutics宣布寻求破产保护。尽管他的失败并不全是数字疗法的问题，更多还是内外部原因的集中爆发，但这对于处于发展初期的数字疗法行业来说无疑是一个警醒。除了Pear，几家数字疗法上市企业也陆续发布了年报。它们的表现如何？有哪些共同的问题所在？有没有一些好的发展模式值得借鉴？动脉网对各家数字疗法上市企业的年报进行了分析。  虽然增速高，但收入不足是普遍困扰最为明显的一点，收入较低是困扰数字疗法上市企业的最大问题之一。号称“数字疗法第一股”的Pear Therapeutics如今已经申请破产保护，但其年报依然值得参考。从年报来看，其在2022年实现收入1269.4万美元，相比前一年420.8万美元的收入大幅提升202%。然而，这些收入在Pear巨大的开销面前只是杯水车薪——在扣除了各种高昂成本后，Pear在2022年的运营亏损竟然高达1.23亿美元。如果对比收入和成本，就会发现“挣得越多，花得更多”是Pear的一个大问题。相比2021年，Pear的收入增加了848.6万美元，但其在2022年相比2021的运营成本却增加了1700万美元，远高于收入的增长。事实上，Pear在上一年同样出现了“挣得越多，亏得更多”的问题。Pear历年年报指标对比（动脉网制图）虽然这显示了Pear的“战线”拉得太长，但核心的问题还是在于收入太少。以游戏数字疗法治疗儿童多动症著称的Akili的收入同样不太理想。它在2022年仅实现32.3万美元的收入，不如2021年53.8万美元的营收。不过，收入的下降主要是因为2022年没有合作收入。如果单纯从产品收入来看，Akili从2021年的18.6万美元已经增加到32.3万美元，增长率为73.7%。Akili历年年报指标对比（动脉网制图）不过，Akili刚刚才在2022年上市，并借此筹集资金实现商业化，如此短的时间内就要见到成效并不容易。此外，Akili的运营成本控制比Pear做得要稍好一些，2022年的运营损失为9068万美元。基于其财务现状来说，仍然可以坚持。Akili在2023年能否在商业化上取得明显进展，获得更多的收入，将决定其是否可以在未来避免Pear的命运。紧随Pear上市的Better Therapeutics的境地较为困难。Pear和Akili的产品至少已经获得了FDA的医疗器械审批，可以开始商业化进程。至今为止，Better仍未拿下FDA审批，因此，其收入连续两年在年报上的体现都是“零”。Better历年年报指标（动脉网制图）在零收入的前提下，即使其将运营成本控制得相当之低，仅有3826万美元的水平，仍旧是无米之炊。为了自救，Better不仅开始裁员，也完成了一轮私募以支撑产品上市所需资金。据称，其高层也在这轮私募中出力颇多。相对而言，早已上市的Dario Health的营收是美股数字疗法上市企业中表现最好的。它在2022年实现了2766万美元的营收，比上一年增加34.8%。尤为难能可贵的是，即使在扣除了各种销售费用后，Dario仍然实现了966万美元的毛利润。Dario历年年报指标（动脉网制图）Dario在收入上远超Pear、Akili和Better三家企业营收的总和，但其运营亏损却只有5681万美元，比Pear和Akili更低。从这个角度而言，Dario的运营是相当务实且可持续的。把范围扩大到美股之外，澳大利亚知名数字疗法企业Tali的收入给人深刻印象。它在2022财年实现了8.81亿澳元（约5.82亿美元）的收入，相比上一财年增长了60.6%之多。比起美股上市的数字疗法企业最多不到三千万级别的收入，Tali的营收无疑是巨无霸级别的。Tali近年年报指标（动脉网制图）不过，仔细分析可以发现，Tali的营收其实也没有表面上那样靓丽。产品收入在2022财年仅有1317万澳元，占其收入比例仅有1.5%，甚至不如前几年的表现。要知道，在2021财年和2020财年，Tali的产品收入尚分别还有3424万澳元和4723万澳元，在其收入中的比例也还有6.2%和7.6%。Tali的收入主要来自其他收入，包括合作研发收到的费用、捐赠收入及研发税务补贴。这其中，研发税务补贴是Tali的主要收入，在2022财年高达6.14亿澳元。尽管收入不少，但Tali的成本也相当夸张，与2021财年相比，Tali的广告及推广成本增加了1.39倍，达到了21.14亿澳元。全年的运营亏损已经达到了69.36亿澳元，较前一年增加了42.8%。量力而行，2B模式有奇效从年报来看，数字疗法上市企业的产品管线分布有两种类型——广泛布局和高度聚焦。广泛布局的代表便是Pear，其具有多个产品管线，且横跨多个适应症。Pear规划了多达17条产品管线，主要适应症除了成瘾戒断，也包括睡眠障碍、抑郁焦虑、偏头痛及肠应激障碍综合征等多种疾病。这些在研管线都需要有相应的投入，以完成产品的设计、探索性试验以及后续的临床试验。这17条产品管线中已有三款产品获得了FDA的审批，并开始了商业化进程。这也使Pear成为了获批数字疗法最多的企业之一。不过，即使到2022年，真正带来收入的主力还是只有一款，其他两款仍处于需要推广投入的阶段。由于收入的增速不如预期，加上当前美国经济和融资环境都不理想，Pear看似广泛的产品管线反而成为了一个拖累，使其成本居高不下。显然，对自身能力有不切实际的估计，将战线铺得太广，是Pear失败的一个原因。当然，这并非Pear独有的问题，实际上也是初创企业的通病。只不过这一现象在Pear身上表现得尤为明显。相比之下，另外几家数字疗法上市企业的产品管线规划就更加聚焦。以Akili为例，其年报显示目前拥有7条产品管线。不过，如果稍加注意就会发现，Akili的7条产品管线中其实只有多动症和认知障碍两种适应症。不过，在2022年初的招股书上，Akili的管线要多得多，达到了13条。显然，Akili选择聚焦产品管线是一个颇为务实的选择。Akili的7条产品线中实际只针对两类适应症（图片来自Akili年报）多动症是其主要适应症，7条产品管线中有多达6条管线是针对不同年龄段的多动症，覆盖了从3岁到成年阶段的患者。比起多种不同的适应症，其产品研发明显更为聚焦，研发进程也要快得多。另外一个适应症则是认知功能障碍训练，尤其是新冠肺炎“脑雾”后遗症是其重要覆盖范围。目前，Akili正与医疗机构合作，评估现有产品对于新冠肺炎患者康复后出现的认知障碍是否具有效果。基于新冠肺炎巨大的人群基数及重复感染的可能性，一旦证实有效或将有较好的前景。这或许也是为何Akili选择保留这一产品管线的重要原因。Dario在早期同样非常聚焦，主要以糖尿病慢病管理为其主要业务。在战略转型之前，Dario已达成了较为稳定的收入。虽然量级不大，维持在700万美元左右，但由于Dario早在2015年就获批了糖尿病数字疗法，商业化进程较早，且其成本控制也非常有效，运营损失也只有不到3000万美元的水平。由于主要针对消费者的糖尿病管理的市场空间巨大，但这一市场的竞争也十分激烈。Dario最初的竞争对手包括雅培、Asensia（前身为拜尔的糖尿病管理部门）、强生Lifescan、罗氏和赛诺菲等药械巨头。这些巨头占据了糖尿病自我管理（BGMS）业务的大部分市场份额，竞争起来并不容易。主要面向消费者的糖尿病慢病管理市场的竞争十分激烈。为此，2020年，Dario开启了转型战略。首先，Dario开始逐步调整商业模式，从直接面向消费者（DTC）开始向B2B2C过渡。利用其消费者解决方案平台的优势，通过向健康计划和雇主等B端销售，在传统健康业务渠道中显著扩大商业增长机会，并降低营销成本。同时，Dario还在2021年通过3次收购进入到其他类型的慢病管理。2021年初，Dario收购Upright Technologies，之后又在2022年初收购Physimax，通过资源整合推出了慢性疼痛数字疗法Dario Move。2021年中，Dario又收购了PsyInnovations，宣布进军行为健康领域。与Pear完全依赖自身拓展多产品管线不一样的是，Dario皆是通过收购成熟产品管线来实现适应症的扩展，不仅可以迅速形成收入，也可以利用其被收购方的资源拓展进一步的商业机会。不得不承认的是，Dario并购的时机极好，2021-2022年正好是数字医疗备受认可的时期，可以较为容易地筹集到收购所需的资金。Dario在B端和C端收入的变化（动脉网制图）在对Pear失败进行分析时，我们指出Pear几乎完全倚赖C端，B端合作并无太大建树。与之相对，Dario的B2B2C战略从收入来看已经初具成效。仅仅在2021年，B端收入还只在其收入中占比4%；到了2022年，C端收入虽然有所下滑，但B端收入从前一年的85.1万美元狂涨18倍，达到了1638万美元，并将B端收入占比大幅提升到了59.2%之多。显然，无论广泛布局和高度聚焦，最为重要的是要量力而行；与此同时，2B对于收入有限的数字疗法来说是非常重要的收入来源。写在最后从几家数字疗法上市企业目前的表现来看，即使在相对成熟的国外市场，数字疗法企业的商业化能力仍有不足，营收较为困难。一旦策略稍有不当就有可能失败。这说明数字疗法仍处于早期阶段，市场仍然需要培育。无论是企业还是投资人，都需要有相当的耐心，等待市场的进一步成熟。当然，不能否认的是，数字疗法的确有其长处所在，比如输出稳定（比人工输出稳定），成本更低（边际成本为0），真实世界数据采集更便捷（使用产品本身就在反馈数据），这些都是数字疗法独特的价值创造，是药物和器械不能够替代的部分。这也注定数字疗法依然有巨大的发展空间。动脉网也将持续关注该领域的发展，并带来最新第一手的报道。*封面图片来源：123rf近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。动脉网，未来医疗服务平台

TALi obtains Australia's nod for cognitive attention trainer device TALi Digital, an ASX-listed developer of diagnostic and therapeutic tools for improving children's attention, has received the Therapeutic Goods Administration's approval for its latest product, ReadyAttentionGo! Available on digital tablets, the software-as-a-medical device serves as a cognitive trainer that helps develop attention skills in children aged 3-10 through digital games. It is an adjunctive tool intended to be used under the direction of a health professional. EpiSoft integrates cancer management platform with My Health Record Episoft is now allowing the users of its medical oncology and administration platform to upload treatment cycle summaries directly to My Health Record. According to a media release, the health IT developer has worked with the Australian Digital Health Agency to integrate its platform with the MHR. The integration now allows cancer care providers to upload treatment event summaries, as well as specialist letters, to MHR via the EpiSoft platform. They can now also access their patient's MHR information via EpiSoft's existing document viewer. Unichem, Life Pharmacy launch unified app Green Cross Health's pharmacy brands Unichem and Life Pharmacy have introduced a unified mobile app for ordering medicines. Available on both iOS and Android devices, the Unichem and Life Pharmacy app connects consumers with their local pharmacy, which in turn can access their personal medication records in real time. Other features of the app include reminders for taking medicines, pre-ordering, and booking pharmacy services. It also has a carer mode which allows a patient's family members to manage their medications on their behalf. The app, according to Green Cross Health, replaces the old text alert system that both Unichem and Life Pharmacy offered their customers to remind them of their next prescription medicine collection. "Our new app is like having a pharmacy in your pocket," said Alison Van Wyk, Unichem and Life Pharmacy Group COO. Medtech Global, Manage My Health announce ALEX integration New Zealand health IT companies Medtech Global and Manage My Health have collaborated to enhance interoperability. Medtech has integrated its Application Layer EXchange (ALEX) API into Manage My Health's patient portal, which is currently used by over 1.5 million users in New Zealand. On top of existing patient engagement features, this integration provides new capabilities to the Manage My Health portal, including real-time appointment booking, patient self-check-in, and secure access to relevant information.